Loading clinical trials...

[18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPhase 1NCT05390814

[18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma

Primary central nervous system (CNS) lymphomas represent 5% of primary brain tumors. More than 90% of them are diffuse large B-cell lymphomas. \[18F\]-Fluorodeoxyglucose positron emission tomography ...

Lead sponsor: Assistance Publique - Hôpitaux de Paris•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 3

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT07104032 · Relapsed/Refractory Primary Central Nervous System Lymphoma

RECRUITINGNA

Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL

NCT07074470 · Primary Central Nervous System Lymphoma (PCNSL)

RECRUITINGPhase 2

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

NCT06175000 · Primary Central Nervous System Lymphoma

RECRUITINGPhase 1/2

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078 · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, and more

RECRUITINGNA

Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

NCT06832267 · Primary Central Nervous System Lymphoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 22, 2025Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment10

Start dateDec 2023

Last updatedAug 22, 2025

Condition

Primary Central Nervous System Lymphoma

Locations shown

Hôpital Pitié Salpêtrière

Paris

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 22, 2025Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions